Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients

• Type: Other Publications
• Date: 2024

Authors

Gonçalves, JM (Author) Other; Carvalho, B (Author) Other; Tuna, R (Author) Other; Polónia, P (Author) Other; Linhares, P (Author) FMUP

Other information

Authenticus ID: P-015-S30

DOI: 10.20944/preprints202404.0320.v1

Abstract (EN): <jats:p>In our study, we investigated the prognostic significance of hematological markers&mdash;NLR (Neutrophil-to-Lymphocyte Ratio), PLR (Platelet-to-Lymphocyte Ratio), and RDW-CV (Red Blood Cell Distribution Width - Coefficient of Variation)&mdash;in 117 glioblastoma patients. Data collected from January 2016 to December 2018 included demographics, clinical scores, and treatment regimens. Unlike previous research, which often examined these markers solely before surgery, our unique approach analyzed them at multiple stages: preoperative, postoperative, and before adjuvant therapies. We correlated these markers with overall survival (OS) and progression-free survival (PFS) using statistical tools, including ANOVA, Cox regression, and Kaplan-Meier survival analyses, employing SPSS version 29.0. Our findings revealed notable variations in NLR, PLR, and RDW-CV across different treatment stages. NLR and PLR decreased after surgery, with some stabilization post-STUPP phase (NLR: p=0.007, &eta;2p=0.06; PLR: p=0.001, &eta;2p=0.23), while RDW-CV increased post-surgery and during subsequent treatments (RDW-CV: p &amp;lt; 0.001, &eta;2p=0.67). Importantly, we observed significant differences between the preoperative phase and other treatment phases. Additionally, higher NLR and RDW-CV at the second-line treatment and disease progression were associated with an increased risk of death (NLR at 2nd line: HR=1.03, p=0.029; RDW-CV at progression: HR=1.14, p=0.004). We proposed specific marker cutoffs that demonstrated significant associations with survival outcomes when applied to Kaplan-Meier survival curves (NLR at 2nd line &amp;lt; 5: p&amp;lt;0.017; RDW-CV at progression &amp;lt; 15: p=0.007). Elevated NLR and RDW-CV at later treatment stages correlated with poorer OS and PFS. No significant preoperative differences were detected. These biomarkers may serve as non-invasive tools for glioblastoma management.</jats:p>

Language: English

Type (Professor's evaluation): Scientific